These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 23471653)

  • 1. Assessing interactions for fixed-dose drug combinations in subcutaneous tumor xenograft studies.
    Wu J
    Pharm Stat; 2013; 12(3):115-9. PubMed ID: 23471653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing interactions for fixed-dose drug combinations in tumor xenograft studies.
    Wu J; Tracey L; Davidoff AM
    J Biopharm Stat; 2012; 22(3):535-43. PubMed ID: 22416839
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating response to antineoplastic drug combinations in tissue culture models.
    Reynolds CP; Maurer BJ
    Methods Mol Med; 2005; 110():173-83. PubMed ID: 15901935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A minimal model of tumor growth inhibition in combination regimens under the hypothesis of no interaction between drugs.
    Magni P; Terranova N; Del Bene F; Germani M; De Nicolao G
    IEEE Trans Biomed Eng; 2012 Aug; 59(8):2161-70. PubMed ID: 22575633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review of the application of response surface methodology in the combination therapy of cancer.
    Carter WH; Wampler GL
    Cancer Treat Rep; 1986 Jan; 70(1):133-40. PubMed ID: 3943113
    [No Abstract]   [Full Text] [Related]  

  • 6. Monitoring Dual VEGF Inhibition in Human Pancreatic Tumor Xenografts With Dynamic Contrast-Enhanced Ultrasound.
    Lamuraglia M; Barrois G; Le Guillou-Buffello D; Santin M; Kerbol A; Comperat E; Coron A; Lucidarme O; Bridal SL
    Technol Cancer Res Treat; 2020; 19():1533033819886896. PubMed ID: 32065066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interval approach to assessing antitumor activity for tumor xenograft studies.
    Wu J; Houghton PJ
    Pharm Stat; 2010; 9(1):46-54. PubMed ID: 19306260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rational combination therapy of vintafolide (EC145) with commonly used chemotherapeutic drugs.
    Reddy JA; Dorton R; Bloomfield A; Nelson M; Vetzel M; Guan J; Leamon CP
    Clin Cancer Res; 2014 Apr; 20(8):2104-14. PubMed ID: 24429878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can taxanes provide benefit in patients with CNS tumors and in pediatric patients with tumors? An update on the preclinical development of cabazitaxel.
    Sémiond D; Sidhu SS; Bissery MC; Vrignaud P
    Cancer Chemother Pharmacol; 2013 Sep; 72(3):515-28. PubMed ID: 23820961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose Optimization for Anticancer Drug Combinations: Maximizing Therapeutic Index via Clinical Exposure-Toxicity/Preclinical Exposure-Efficacy Modeling.
    Bottino DC; Patel M; Kadakia E; Zhou J; Patel C; Neuwirth R; Iartchouk N; Brake R; Venkatakrishnan K; Chakravarty A
    Clin Cancer Res; 2019 Nov; 25(22):6633-6643. PubMed ID: 31320596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assays for in vitro and in vivo synergy.
    Teicher BA
    Methods Mol Med; 2003; 85():297-321. PubMed ID: 12710216
    [No Abstract]   [Full Text] [Related]  

  • 12. The potential clinical promise of 'multimodality' metronomic chemotherapy revealed by preclinical studies of metastatic disease.
    Kerbel RS; Shaked Y
    Cancer Lett; 2017 Aug; 400():293-304. PubMed ID: 28202353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An Unbiased Oncology Compound Screen to Identify Novel Combination Strategies.
    O'Neil J; Benita Y; Feldman I; Chenard M; Roberts B; Liu Y; Li J; Kral A; Lejnine S; Loboda A; Arthur W; Cristescu R; Haines BB; Winter C; Zhang T; Bloecher A; Shumway SD
    Mol Cancer Ther; 2016 Jun; 15(6):1155-62. PubMed ID: 26983881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
    Lobell RB; Omer CA; Abrams MT; Bhimnathwala HG; Brucker MJ; Buser CA; Davide JP; deSolms SJ; Dinsmore CJ; Ellis-Hutchings MS; Kral AM; Liu D; Lumma WC; Machotka SV; Rands E; Williams TM; Graham SL; Hartman GD; Oliff AI; Heimbrook DC; Kohl NE
    Cancer Res; 2001 Dec; 61(24):8758-68. PubMed ID: 11751396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical pharmacokinetic/pharmacodynamic models to predict synergistic effects of co-administered anti-cancer agents.
    Goteti K; Garner CE; Utley L; Dai J; Ashwell S; Moustakas DT; Gönen M; Schwartz GK; Kern SE; Zabludoff S; Brassil PJ
    Cancer Chemother Pharmacol; 2010 Jul; 66(2):245-54. PubMed ID: 19841922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Theoretical investigation of the efficacy of antiangiogenic drugs combined to chemotherapy in xenografted mice.
    Lignet F; Benzekry S; Wilson S; Billy F; Saut O; Tod M; You B; Adda Berkane A; Kassour S; Wei MX; Grenier E; Ribba B
    J Theor Biol; 2013 Mar; 320():86-99. PubMed ID: 23261980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation.
    Bahri M; Fleurence J; Faraj S; Ben Mostefa Daho M; Fougeray S; Birklé S
    J Vis Exp; 2019 Jan; (143):. PubMed ID: 30735151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The challenge of selecting the 'right' in vivo oncology pharmacology model.
    Firestone B
    Curr Opin Pharmacol; 2010 Aug; 10(4):391-6. PubMed ID: 20634135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Experimental design and sample size determination for testing synergism in drug combination studies based on uniform measures.
    Tan M; Fang HB; Tian GL; Houghton PJ
    Stat Med; 2003 Jul; 22(13):2091-100. PubMed ID: 12820275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Broad-spectrum Preclinical Antitumor Activity of Eribulin (Halaven®): Combination with Anticancer Agents of Differing Mechanisms.
    Asano M; Matsui J; Towle MJ; Wu J; McGonigle S; DE Boisferon MH; Uenaka T; Nomoto K; Littlefield BA
    Anticancer Res; 2018 Jun; 38(6):3375-3385. PubMed ID: 29848686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.